

United States Patent and Trademark Office

C (C

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/601,345	06/19/2003	Andreas Gerardus Uitterlinden	KILS121089	5017
26389	7590 11/03/2005		EXAMINER	
CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC 1420 FIFTH AVENUE SUITE 2800			SALMON, KATHERINE D	
			ART UNIT	PAPER NUMBER
SEATTLE, WA 98101-2347			1634	-

DATE MAILED: 11/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	10/601,345	UITTERLINDEN ET AL.		
Office Action Summary	Examiner	Art Unit		
	Katherine Salmon	1634		
The MAILING DATE of this communicate Period for Reply	tion appears on the cover sheet v	vith the correspondence address		
A SHORTENED STATUTORY PERIOD FOR WHICHEVER IS LONGER, FROM THE MAIL - Extensions of time may be available under the provisions of 3' after SIX (6) MONTHS from the mailing date of this communic - If NO period for reply is specified above, the maximum statuto - Failure to reply within the set or extended period for reply will, Any reply received by the Office later than three months after earned patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF THIS COMMUN 7 CFR 1.136(a). In no event, however, may a lation. ry period will apply and will expire SIX (6) MC by statute, cause the application to become the	ICATION. Treply be timely filed NTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).		
Status				
 1) Responsive to communication(s) filed of the communication (s) filed of the commun	This action is non-final. allowance except for formal ma			
Disposition of Claims				
4) ⊠ Claim(s) <u>1-30</u> is/are pending in the app 4a) Of the above claim(s) is/are v 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☒ Claim(s) <u>1-30</u> are subject to restriction	withdrawn from consideration.			
Application Papers				
9) The specification is objected to by the E 10) The drawing(s) filed on is/are: a Applicant may not request that any objection Replacement drawing sheet(s) including the 11) The oath or declaration is objected to be	D accepted or b) objected to n to the drawing(s) be held in abey e correction is required if the drawir	ance. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-3) Information Disclosure Statement(s) (PTO-1449 or PT Paper No(s)/Mail Date	-948) Paper N	v Summary (PTO-413) o(s)/Mail Date f Informal Patent Application (PTO-152) 		

Application/Control Number: 10/601,345 Page 2

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-26 and 29-30, drawn to a method of determining susceptibility to a bone fracture and treating to decrease the risk of a bone fracture, classified in class 514, subclass 44.
 - II. Claims 27-28, drawn to a kit comprising nucleic acid primer molecules of estrogen receptor and vitamin D receptor genes, means for determining the presence of px haplotype and baT haplotype, and means for indicating a correlation between the presence of haplotype and risk of bone fracture, classified in class 536, subclass 24.33.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of Invention III can be used for the methods of determining susceptibility and treatment to decrease the risk of a bone fracture or the product could be used to make antisense nucleic acids for gene therapy. The search for each invention presents a serious burden, as the

Application/Control Number: 10/601,345

Art Unit: 1634

searches for each are not coextensive in scope. Art relating to the methods of determining susceptibility and treatment would not necessarily provide descriptive information for nucleic acid primer molecules for amplification of the estrogen receptor or the vitamin D receptor.

4. The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

Application/Control Number: 10/601,345 Page 4

Art Unit: 1634

"Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter and because Inventions I-III required different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/601,345 Page 5

Art Unit: 1634

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Katherine Salmon whose telephone number is (571) 272-3316. The examiner can normally be reached on Monday -Friday 8AM-430PM.

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (571) 272-0745. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Katherine Salmon Examiner

Kathemo Solmon 10/27/05

Art Unit 1634

10/29/05